Arrowhead Shares Jump 6.95% on Surge in AI-Driven Cardiac Diagnostics Market Forecast
ARWR•Arrowhead Pharmaceuticals shares rose 6.95% after Wall Street signaled strong interest in AI-driven cardiac diagnostics, as the global AI cardiology market is projected to expand from $2.78 billion this year to $14 billion by 2034. Hospitals eye machine-learning tools to cut diagnostic backlogs, driving institutional capital into Arrowhead’s sector.
1. Market-Driven Share Uplift
Arrowhead Pharmaceuticals shares gained 6.95% on May 12, reflecting investor appetite for companies positioned in the surge of AI-enabled cardiac diagnostics. The move placed Arrowhead among the five leading addresses of institutional capital in the sector, alongside VentriPoint Diagnostics, BridgeBio Pharma, Bristol Myers Squibb and Amgen.
2. AI Cardiology Market Expansion
The global AI cardiology market, valued at $2.78 billion in 2026, is forecast to exceed $14 billion by 2034 as hospitals adopt machine-learning tools to streamline diagnostic workflows. Rapid growth in interventional cardiology devices and wearable ECG monitoring, growing at over 23% annually, underscores the sector’s appeal to investors.
